Aftab Blake has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Blake Aftab is the Chief Scientific Officer of Adicet Bio, Inc., a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. In the latest SEC filing as of 2026-01-27 (CIK 0001886986), he is listed as CSO with no reported purchases or sales. He leads the company’s scientific strategy and translational research for gamma delta T cell programs, including efforts around ADI-001 and related therapies.
Role
Insider
Notability
42/100
Board memberships
Adicet Bio, Inc.
Awards & honors
Oversees scientific strategy and translational R&D for allogeneic gamma delta T cell therapies at Adicet Bio
Guides early-stage development programs and translational research efforts for gamma delta T cell therapy platforms
Blake Aftab is the Chief Scientific Officer of Adicet Bio, Inc., a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. In the latest SEC filing as of 2026-01-27 (CIK 0001886986), he is listed as CSO with no reported purchases or sales. He leads the company’s scientific strategy and translational research fo…
How many SEC Form 4 filings has Aftab Blake submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Aftab Blake's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
